Compare Chubb Ltd (CB) vs TG Therapeutics Inc (TGTX) Price & Performance

Chubb Limited (CB) trades at $343.12, down 1.49% on the day, with a neutral technical signal. The stock shows strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $7.26 versus $6.77 expected, and a net income margin of 17.96% for 2025. Revenue has grown from $43.1B in 2022 to $59.8B in 2025, with further growth projected. A recent dividend of $1.02 was declared for H1-26, payable July 2, 2026.

The outlook remains positive given analyst consensus favoring Buy ratings (52.38%) and a price target of $366.83, implying ~7% upside. Risks include potential volatility from macroeconomic factors and competitive pressures in the insurance sector. The company’s disciplined underwriting and investment income growth support long-term value, but investors should weigh valuation multiples against sector peers.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.